MedTrace Logo

Project BEST: Buprenorphine Entry Into Substance Abuse Treatment

NCT02583243 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 209

Last updated 2020-04-03

No results posted yet for this study

Summary

Project BEST is a clinical project funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) to increase treatment to opiate dependent patients with mental illness in New Haven, CT and to prospectively follow everyone enrolled in buprenorphine care for as long as the individual takes buprenorphine to track the success of buprenorphine for the maintenance of opiate dependence.

Conditions

  • Opioid-related Disorders
  • HIV Infections
  • Hepatitis C, Chronic
  • Depression

Interventions

BEHAVIORAL

MET/CBT based individualized counseling

Manualized counseling with the first four week being MET followed by 8 weeks of CBT

DRUG

Buprenorphine

Target dose in stabilization is 16 mg of buprenorphine to be taken sublingually once daily.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Frederick L Altice, MD · Yale University AIDS Program

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02583243 on ClinicalTrials.gov